HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial

Trials

Koenraad F van der Sluijs⁶  Marcus J Schultz³  Manu Malbrain^1,10  David P Mackie⁵  Bert G Loef¹  Marcel M Levi⁸  Paul Knape⁵  Nicole P Juffermans³  Barry Dixon⁷  Kirsten Colpaert⁹  Berry Cleffken²  Jan M Binnekade³  Johannes Muller⁴  Gerie J Glas³ 

[1] Department of Intensive Care, Martini Hospital, Groningen, the Netherlands;Department of Intensive Care, Maasstad Hospital, Rotterdam, the Netherlands;Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, the Netherlands;Department of Intensive Care, University Hospital Gasthuisberg, Leuven, Belgium;Department of Intensive Care, Red Cross Hospital, Beverwijk, the Netherlands;Laboratory of Experimental Intensive Care and Anesthesiology (L · E · I C · A), Department of Intensive Care Medicine, Academic Medical Center, M0-210, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands;Department of Intensive Care, St Vincent’s Hospital, Melbourne, Australia;Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands;Department of Intensive Care, Ghent University Hospital, Ghent, Belgium;Department of Intensive Care, Ziekenhuis Netwerk Antwerpen - Stuivenberg, Antwerp, Belgium

关键词: Mechanical ventilation;    Heparin;    Nebulization;    Pulmonary coagulopathy;    Inhalation trauma;   

Others  :  807210
DOI  :  10.1186/1745-6215-15-91

 received in 2013-05-21, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Pulmonary coagulopathy is a hallmark of lung injury following inhalation trauma. Locally applied heparin attenuates lung injury in animal models of smoke inhalation. Whether local treatment with heparin benefits patients with inhalation trauma is uncertain. The present trial aims at comparing a strategy using frequent nebulizations of heparin with standard care in intubated and ventilated burn patients with bronchoscopically confirmed inhalation trauma.

Methods

The Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized HEParin versus Placebo in BURN Patients with Inhalation Trauma (HEPBURN) is an international multi-center, double-blind, placebo-controlled, two-arm study. One hundred and sixteen intubated and ventilated burn patients with confirmed inhalation trauma are randomized to nebulizations of heparin (the nebulized heparin strategy) or nebulizations of normal saline (the control strategy) every four hours for 14 days or until extubation, whichever comes first. The primary endpoint is the number of ventilator-free days, defined as days alive and breathing without assistance during the first 28 days, if the period of unassisted breathing lasts for at least 24 consecutive hours.

Discussion

As far as the authors know, HEPBURN is the first randomized, placebo-controlled trial, powered to investigate whether local treatment with heparin shortens duration of ventilation of intubated and ventilated burn patients with inhalation trauma.

Trial registration

NCT01773083 (http://www.clinicaltrials.gov webcite), registered on 16 January 2013.

Recruiting. Randomisation commenced on 1 January 2014.

【 授权许可】

   
2014 Glas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bloemsma GC, Dokter J, Boxma H, Oen IM: Mortality and causes of death in a burn centre. Burns 2008, 34:1103-1107.
• [2]Hassan Z, Wong JK, Bush J, Bayat A, Dunn KW: Assessing the severity of inhalation injuries in adults. Burns 2010, 36:212-216.
• [3]Traber DL, Maybauer MO, Maybauer DM, Westphal M, Traber LD: Inhalational and acute lung injury. Shock 2005, 24(Suppl 1):82-87.
• [4]Evers LH, Bhavsar D, Mailander P: The biology of burn injury. Exp Dermatol 2010, 19:777-783.
• [5]Hofstra JJ, Vlaar AP, Knape P, Mackie DP, Determann RM, Choi G, van der Poll T, Levi M, Schultz MJ: Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J Trauma 2011, 70:1389-1397.
• [6]Enkhbaatar P, Cox RA, Traber LD, Westphal M, Aimalohi E, Morita N, Prough DS, Herndon DN, Traber DL: Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med 2007, 35:2805-2810.
• [7]Enkhbaatar P, Esechie A, Wang J, Cox RA, Nakano Y, Hamahata A, Lange M, Traber LD, Prough DS, Herndon DN, Traber DL: Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin Sci (Lond) 2008, 114:321-329.
• [8]Mizutani A, Enkhbaatar P, Esechie A, Traber LD, Cox RA, Hawkins HK, Deyo DJ, Muramaki K, Noguchi T, Traber DL: Pulmonary changes in a mouse model of combined burn and smoke inhalation-induced injury. J Appl Physiol 2008, 105:678-684.
• [9]Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002, 18:236-241.
• [10]Dries DJ: Management of burn injuries - recent developments in resuscitation, infection control and outcomes research. Scand J Trauma Resusc Emerg Med 2009, 17:14. BioMed Central Full Text
• [11]Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM: Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009, 30:249-256.
• [12]Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN: Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine therapy. J Burn Care Rehabil 1998, 19:210-212.
• [13]WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. [http://www.wma.net/en/30publications/10policies/b3/ webcite].
• [14]Moher D, Schulz KF, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991.
• [15]Clark CJ, Reid WH, Gilmour WH, Campbell D: Mortality probability in victims of fire trauma: revised equation to include inhalation injury. Br Med J (Clin Res Ed) 1986, 292:1303-1305.
• [16]Albright JM, Davis CS, Bird MD, Ramirez L, Kim H, Burnham EL, Gamelli RL, Kovacs EJ: The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury. Crit Care Med 2012, 40:1113-1121.
• [17]The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edition. Boston: Little, Brown & Company; 1994:253-256.
• [18]Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
• [19]Belgian Outcome for Burn Injury Study Group: Development and validation of a model for prediction of mortality in patients with acute burn injury. Br J Surg 2009, 96:111-117.
• [20]Ortiz RM, Cilley RE, Bartlett RH: Extracorporeal membrane oxygenation in pediatric respiratory failure. Pediatr Clin North Am 1987, 34:39-46.
• [21]Vincent JL, Moreno R, Takala J, Willatts S, De MA, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
• [22]Murray JF, Matthay MA, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138:720-723.
• [23]Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS: Acute respiratory distress syndrome: the Berlin definition. JAMA 2012, 307:2526-2533.
• [24]Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O’Neal PV, Keane KA, Tesoro EP, Elswick RK: The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002, 166:1338-1344.
• [25]Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R: Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 2001, 286:2703-2710.
• [26]Mackie DP, Spoelder EJ, Paauw RJ, Knape P, Boer C: Mechanical ventilation and fluid retention in burn patients. J Trauma 2009, 67:1233-1238.
• [27]Warden GD, Wilmore DW, Rogers PW, Mason AD, Pruitt BA Jr: Hypernatremic state in hypermetabolic burn patients. Arch Surg 1973, 106:420-427.
• [28]A’Court CH, Garrard CS, Crook D, Bowler I, Conlon C, Peto T, Anderson E: Microbiological lung surveillance in mechanically ventilated patients, using non-directed bronchial lavage and quantitative culture. Q J Med 1993, 86:635-648.
• [29]Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14:R180. BioMed Central Full Text
• [30]Chung KK, Wolf SE, Renz EM, Allan PF, Aden JK, Merrill GA, Snelhamer MC, King BT, White CE, Bell DG, Schwacha MG, Wanek SM, Wade CE, Holcomb JB, Blackbourne LH, Cancio LC: High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. Crit Care Med 2010, 38:1970-1977.
• [31]Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
• [32]Mitra B, Wasiak J, Cameron PA, O'Reilly G, Dobson H, Cleland H: Early coagulopathy of major burns. Injury 2012, 44(1):40-3.
• [33]D’agostino RB, Belanger A, D’agostino RB Jr: A suggestion for using powerful and informative tests of normality. Amer Statist 1990, 44:316-321.
• [34]Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958, 53:457-481.
• [35]ICH Guidelines: Good Clinical Practice E6, Published in the Federal Register, 9 May 1997, Vol. 62, No. 90.25691-25709. [http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html webcite]
• [36]Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000, 161:454-462.
• [37]Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989, 84:695-705.
• [38]Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998, 24:33-44.
• [39]Levi M, Schultz MJ, Rijneveld AW, Van Der Poll T: Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003, 31:S238-S242.
• [40]Schultz MJ, Determann RM, Royakkers AA, Wolthuis EK, Korevaar JC, Levi MM: Bronchoalveolar activation of coagulation and inhibition of fibrinolysis during ventilator-associated lung injury. Crit Care Res Pract 2012, 2012:961784.
• [41]de Boer JD, Majoor CJ, Van t Veer C, Bel EH, Van Der Poll T: Asthma and coagulation. Blood 2012, 119:3236-3244.
• [42]Tapson VF: The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:71-77.
• [43]Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR: The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. Expert Opin Investig Drugs 2008, 17:905-916.
• [44]Chapman HA, Allen CL, Stone OL: Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986, 133:437-443.
• [45]Yasui H, Gabazza EC, Taguchi O, Risteli J, Risteli L, Wada H, Yuda H, Kobayashi T, Kobayashi H, Suzuki K, Adachi Y: Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin Appl Thromb Hemost 2000, 6:202-205.
• [46]Enkhbaatar P, Herndon DN, Traber DL: Use of nebulized heparin in the treatment of smoke inhalation injury. J Burn Care Res 2009, 30:159-162.
• [47]Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004, 109:2698-2704.
• [48]Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA: Coagulation and inflammation in acute lung injury. Thromb Haemost 2002, 88:17-25.
• [49]Finigan JH: The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res 2009, 77:35-38.
• [50]Hochart H, Jenkins PV, Smith OP, White B: Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006, 133:62-67.
• [51]Fan SQ, Cai JL, Qin LY, Wang ZH, Liu ZZ, Sun ML: Effect of heparin on production of transforming growth factor (TGF)-beta1 and TGF-beta1 mRNA expression by human normal skin and hyperplastic scar fibroblasts. Ann Plast Surg 2008, 60:299-305.
• [52]Thomas R, Brooks T: Common oligosaccharide moieties inhibit the adherence of typical and atypical respiratory pathogens. J Med Microbiol 2004, 53:833-840.
• [53]Matzner Y, Marx G, Drexler R, Eldor A: The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984, 52:134-137.
• [54]Leculier C, Benzerara O, Couprie N, Francina A, Lasne Y, Archimbaud E, Fiere D: Specific binding between human neutrophils and heparin. Br J Haematol 1992, 81:81-85.
• [55]Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993, 82:3253-3258.
• [56]Cox CS Jr, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN: Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993, 176:339-349.
• [57]Yip LY, Lim YF, Chan HN: Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre. Burns 2011, 37:1154-1160.
• [58]Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, van der Poll T, Levi M, Schultz MJ: Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010, 23:105-111.
• [59]Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT: Lung deposition and clearance of inhaled (99 m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999, 160:1653-1658.
• [60]Markart P, Nass R, Ruppert C, Hundack L, Wygrecka M, Korfei M, Boedeker RH, Staehler G, Kroll H, Scheuch G, Seeger W, Guenther A: Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2010, 23:161-172.
• [61]Dixon B, Santamaria JD, Campbell DJ: A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008, 12:R64. BioMed Central Full Text